Satish Vankayalapati – Chairman
Satish Vankayalapati is the Founder and Chief Executive Officer of UrbanX Global, which invests in the technologies and supporting infrastructure powering the new economy. The firm’s focus areas include technology-enhanced healthcare and medical devices, platforms for enhancing and securing the online environment, and real estate aligned with the new dynamics of how we work, live, and deliver services.
Satish has extensive experience in real estate, technology and healthcare, across all facets of the value-chain, from acquisition through development and divestment and exit. Satish recently served as the President of Capri Capital Partners, the $3.6 billion real estate asset management firm. Prior to Capri, Satish served as an Advisor to a $13 billion emerging market-focused private equity firm, where he provided guidance to the senior investment and operating leadership related to their healthcare assets in excess of $1 billion.
Satish was a Partner at McKinsey and Company, where he was a co-leader in the real estate and infrastructure practice, and as well as a member of the technology practice. He advised clients in strategic mergers and acquisitions in excess of $100 billion. He served some of the largest real estate developers, technology companies and private equity firms globally. He also helped clients conceptualize and execute green-field development projects in excess of $1 billion.
Satish holds a Master of Business Administration degree from the Kellogg School of Management, Northwestern University, and an undergraduate degree in Mechanical Engineering.
Robert J. Rudelius – President & Chief Executive Officer
Robert Rudelius is the Chief Executive Officer of MedicaMetrix, a medical technology company which is at the forefront of innovation in prostate care. MedicaMetrix offers a comprehensive prostate disease diagnosis and management platform by blending together devices with data analytics and AI. MedicaMetrix is headquartered in Cambridge, Massachusetts, and has affiliate operations in the Netherlands and India.
Mr. Rudelius is also the Managing Partner of the Healthcare vertical of UrbanX Group, an investment company focused on innovation markets. He serves as a member of the Axogen, Inc. Board of Directors since September 2011. From 2013 to 2019 he served as the Chairman of the Company’s Audit Committee and a member of the Compensation Committee. Axogen (NASDAQ: AXGN) is the leader in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair.
Since 2018, Mr. Rudelius has served on the Board of Directors for PetVivo Holdings, Inc., where he is Chairman of the Compensation Committee and a member of the Governance Committee. PetVivo (NASDAQ: PETV) is an emerging biomedical device company focused on developing innovative human medical device technologies for the companion animal market.
Since 2001, Mr. Rudelius has been the Managing Director and CEO of Noble Ventures, LLC, a company he founded that provides advisory services to medical technology, biosciences and information technology companies. Earlier in his career, Mr. Rudelius has served in several senior leadership roles such as CEO of Media DVX, Inc., a media technology company; President and COO of Control Data Systems (acquired by British Telecom), as well as Managing Partner of AT&T Solutions.
From 1990 through 1995, Mr. Rudelius was a Partner at McKinsey & Company, where he served as a leader of Information Technology & Systems practices in the United Kingdom and Japan.
He began his career at Arthur Andersen & Co. where he was a leader of the firm’s financial accounting systems consulting practice and designed and implemented large systems for technology and government clients. Mr. Rudelius has an MBA from the Kellogg School of Management, Northwestern University in Evanston, Illinois.
Christopher G. Lafarge – Chief Operating Officer
Mr. LaFarge is an operationally focused director and executive, with extensive experience as a senior executive in closely held companies including entrepreneurial start-ups, high-growth, and mature organizations. He has also served on the Boards of several privately held corporations, as well as educational and non-profit boards.
He has acquired deep experience in the areas of product development, life sciences, QA systems, and financing. An energetic and outgoing executive who understands business issues and focuses on leading by building relationships and collaborating at all levels.
Mr. LaFarge has provided strategic leadership for early stage, life science, and medical device companies in the fields of urology, anesthesiology, intensive care, and neuroscience as well as companies in the oil and gas, management consulting, and natural resources industries. He has significant experience in raising both debt and equity capital.
Since 2019, Mr. LaFarge has been the COO of Bach Pharma, a pharmaceutical company developing therapeutics for the treatment of neurodegenerative diseases like ALS and Parkinson’s and other life-threatening redox and inflammation-related illnesses like radiation, chemical poisoning, or viral and bacterial infections like pneumonia.
Christopher is also working with an artificial intelligence company in Atlanta GA, IMARC AI, to develop AI-based decision support for ICU/ER physicians as well as other healthcare AI applications.
From 2004-2018, He was the President and CEO of MedicaMetrix, Inc., the predecessor organization to MedicaMetrix LLC where he invented ProstaMetric®, obtained European regulatory approval (CE Marking certification), and created scalable, manufacturing procedures for the device, and developed a quality management system which received an ISO 13485 certification.
From 1994-2003 he was the CFO and Director of Business Development for IIC, which was created to build and market expert systems, intelligent devices, and control systems for the exploration, drilling, and production segments of the “upstream” petroleum industry.
Christopher also has a wide range of Board experience, working as part of both management teams and boards as well as start-ups and recently capitalized companies with newly organized boards. Mr. LaFarge has an MBA from the Yale School of Management, an MFS in environmental Science from Yale U., and a BA in Biology from Harvard College.
Richard C. Carlson – Executive Vice President – Business Development
Rick Carlson is the Executive Vice President – Marketing and Global Business Development. He returns to the company after having served as the Vice President of International Marketing from 2015 to 2017. In that position, he was responsible for setting up a subsidiary company in the Netherlands and initiated a multi-center clinical trial in the United Kingdom and Europe. Rick identified and built relationships with key urology constituency groups to establish support for the product, and developed support systems to manage distribution, order processing and after-sales service. He also designed clinical protocols for conducting scientific studies including the collection and analysis of data.
Rick has more than 20 years of prostate disease market experience and has been involved in companies focused on the specialty of urology for more 30 years. Rick has proven leadership track record in the US, Europe and other global markets, and he is poised to scaling MedicaMetrix rapidly in both the US, and in international markets. Throughout all of his previous positions, Rick has developed relationships with key urologists and other physicians in major medical centers throughout U.S., Europe and Japan. Prior to MedicaMetrix, Rick served as the CEO of ProUroCare Medical, Inc., a developer of a mechanical imaging device that creates a real-time color image of the prostate.
During the hiatus from MedicaMetrix between 2017 and present, Rick has been serving as the Director of Business Development for a company with an innovative product and technology for eliminating biofilm and other bacteria in water-based facilities. His primary contributions at this company was to develop a U.S. and an international dealer network which resulted in a 65% increase in sales (yoy) in 2019.
Earlier in his career, Rick identified clinical and economic benefits of a range of medtech devices and products, developed requirements for obtaining clinical validation and regulatory approvals in the US and Europe. He also designed training materials and scalable in-service training programs for physicians, and developed product, clinical, regulatory and commercialization strategies for marketing the products.
Rick has created unique medtech device business models, reimbursement strategy, billing models to maximize revenue, acquired and helped submit more than 20 patents to provide a strong intellectual property position. He also helped four medical device companies to develop go-to-market strategies, developed channel and distribution strategies.
His previous urology work experience in the medical device industry includes extended commitments at a gamut of industry leaders such as American Medical Systems, C. R. Bard, Boston Scientific and Advanced Surgical Intervention, Medtronic, and Vicon Systems.
Rick has a BA with honors in Business/Economics from the University of Minnesota, and an MBA with honors in Marketing from the Carlson School of Business at the University of Minnesota.
Daniel E. Larkin – Director, Medical Innovation
Dr. Daniel E. Larkin is the Director of Medical Innovation at MedicaMetrix, LLC. His mission is to design and develop medical devices that translate into improvements in the delivery of medical care and improve the patient’s overall experience.
Dr. Larkin is the inventor of several medical devices, including an innovative IV securement device that MedicaMetrix is planning to launch that streamlines, standardizes and transforms infusion care.
Dr. Larkin is a family physician in Saint Paul, Minnesota and is affiliated with the M Health Fairview system. He has a full spectrum Family Medicine practice for 20 years in the Fairview Legacy HealthEast system. He has provided hospital-based care at HealthEast St. John’s Hospital, St. Joseph’s Hospital, and other area hospitals in the Twin Cities. He has a passion for thinking though methods to better the delivery of care through innovative medical devices.
Dr. Larkin is an Adjunct Faculty Preceptor at the University of Minnesota since 2004, where he was recognized as the Preceptor of the Year at the University of Minnesota Medical School. He has also been named twice as a Top Doctor by Minnesota Monthly Magazine.
Dr. Larkin graduated from the Medical School of Wisconsin in 1995 and received a premed science degree from the University of Minnesota and a BA from St. John’s University.
Jeff Muzzy – Chief Technology
Jeff Muzzy is the Chief Technology Officer of MedicaMetrix. He is a talented leader who has architected, designed, and operated new technology-based products and services to market with global scale. Jeff has worked thirty-five years in the tech industry for multibillion-dollar companies and startups.
Jeff was a leader on teams designed and released. Microsoft Windows (1.0 – XP, Win 10), Microsoft Word, Excel, Exchange and System architect for MSN Backend Services and Application Architecture. These systems support multiple billions of requests per day. An example is MSN Weather, Sports and News.
Jeff has eleven years in the IOT (Internet of Thing) in the automotive sector designing connected car distribution. Jeff has worked as a partner for Ford (Sync), GM (OnStar), Nissan- Renault (Connect and Alliance), Chrysler-Fiat (UConnect). In addition, Jeff has created several hardware and software used by millions of users daily.
Jeff is a board member on a few technology companies including an AI (Artificial Intelligence) that is developing computer vision and alerting for automobiles, and a technology company for process automation of sports equipment.
Nandini Murthy – Principal, Regulatory Affairs And Quality Systems
Nandini Murthy is the Principal, Regulatory Affairs and Quality Systems at MedicaMetrix. She is responsible for all FDA and other product approvals and certifications.
Ms. Murthy has over 20 years of work experience in regulatory affairs, clinical and quality assurance functions with multiple device specialties. She has authored numerous, successful FDA submissions including a de novo, a modular PMA, a HDE, original PMAs, several original IDEs, pre-Submissions, PMA and IDE Supplements and 510(k)s for novel products including implantable devices, sensor/monitoring tools and diagnostic devices.
She has also worked on combination drug-device combination products, regulated by either CDRH or CDER as Lead Review Center, supporting the medical device/CMC/design controls deliverables for FDA submissions. She has experience with product approvals for the EU (CE Mark), Japan and Canadian markets. She has led projects with complex submissions, where she has both managed a team and where necessary, written or executed on the various document deliverables in a hands-on manner. Ms. Murthy has a successful track record of on-time execution and FDA approvals.
In addition to her core expertise in regulatory affairs, Ms. Murthy has designed and executed complex clinical trials and established quality systems to ISO 13485 and FDA Quality System requirements. She has helped early stage and more established larger companies develop their quality systems consistent with their stage of device development. She has experience in developing plans for Quality Systems projects, including tactically prioritizing and directing focus, and updating/communicating plans and status with Management. She has a record of working collaboratively with teams (located both within the US and OUS), building support and consensus towards compliance.
Ms. Murthy served on the Management team of several companies, providing leadership to regulatory efforts, blending a strategic solution-oriented approach with strong tactical abilities. Her work experience in regulatory affairs and quality systems spans a gamut of medical device companies including USCI Division of C.R. Bard, InfraReDx, Cyberkinetics, Aspect Medical Systems, Thoratec and Hologic. Ms. Murthy has served as the key quality systems resource, responsible for developing Quality System to support design/development activities and ensuring that applicable Design History File (DHF) documents were ready for premarket submissions.
Ms. Murthy is a frequent speaker at various clinical and regulatory conferences and meetings. She is a member of the Regulatory Affairs Professional Society (RAPS), Medical Development Group (MDG). She holds an MS in Environmental Science from University of Massachusetts, Boston, and a BS in Chemistry from Bangalore University.
Peter N. Madras, MD – Medical Advisor
Dr. Madras retired from his career as a transplant and vascular surgeon after a 7-year stint at the University of Toronto and 23 years at Harvard and the Beth Israel Deaconess Medical Center (BIDMC). During his career, Dr. Madras worked in the biotech industry, including the Avco Everett Research Laboratory where he led the medical group in developing the Intra-Aortic Balloon pump, and was medical director for Grace Biomedical developing bio-hybrid artificial organs.
In June 2020, Peter completed serving a 4-year term as the President of the Medical Development Group of Boston and is currently a lecturer in the Institute of Medical Sciences and Engineering at MIT. He serves on the boards of several start-up and high-growth companies.
Dr. Madras received his MD from McGill University.
John A. Libertino, MD – Medical Advisor
Dr. John A. Libertino is a renowned urologist affiliated with Emerson Hospital in Concord, MA. His clinical interests include urologic surgery, adrenal cancer, renal cancer, bladder cancer, continent diversions, prostate cancer, urethral cancer, and testes cancer.
Prior to joining Emerson, Dr. Libertino held several senior positions at Lahey Clinic Medical Center, including those as CEO and Chairman, Chairman of the Division of Surgery, Vice Chairman of the Board of Trustees and Director of the Sophia Gordon Cancer Center.
Dr. Libertino completed his residency in urology at Yale-New Haven Medical Center and is a graduate of Georgetown University School of Medicine. He is board-certified in urology and surgery. As a frequent contributor to medical journals, Dr. Libertino served as Editor-in-Chief of The American Journal of Urology Review.
Mark G. Garzotto, MD – Medical Advisor
Dr. Mark Garzotto is a urologist affiliated with OHSU Hospital and the Portland VA Medical Center and is practicing in Portland, OR. Dr. Garzotto has over 30 years of experience in the medical field and specializes in diseases of the urinary tract and the male reproductive system. This includes areas of the bladder, urethra, kidneys, and prostate.
Dr. Garzotto’s career in medicine began in 1990, when he graduated with his Medical Degree from the Louisiana State University School of Medicine in New Orleans, LA. After graduating from medical school, Dr. Garzotto completed residency at University of Florida College of Medicine, Urology and General Surgery.
Prof. Raj Persad – Medical Advisor
Professor Raj Persad has been a practicing Uro-Oncology surgeon with an international reputation for innovation and research, since 1996. He specializes in Bladder, Prostate and Kidney Cancer. He has served on key National and International committees for guideline development, service reform and research such as the National Cancer Intelligence Network, National Cancer Research Institute, NIHR-RfPB, NICE, IBCG, BAUS Section of Oncology and Cancer Research UK.
Prof. Persad is one of the country’s leading pelvic cancer surgeons bringing with him advanced surgical techniques with him from his training abroad in the US and Europe. He leads an active research program and is the recipient of £5m in research grants. He has over 230 published scientific papers in urological cancer and 5 books.
He is a University examiner for higher degrees for London, Oxford, Cardiff, and Bristol and has been an examiner for the College of Surgeons and Tutor in Surgical skills. He is a member of the Colorectal Health Technology Co-operative and is also the Lead Clinician in the Bristol Biomedical Research Unit prostate cancer program. He has research interests in focal therapy of prostate cancer and novel therapies in castrate resistant prostate cancer and metastatic kidney cancer.
He is a key opinion leader in several areas of urology and, along with Professor David Gillatt, has established one of the country’s leading medical robotics programs (Bristol Urological Institute in conjunction with the University of Bristol and the University of the West of England). He serves on the BAUS Section of Andrology as a National expert in this area.